<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580108</url>
  </required_header>
  <id_info>
    <org_study_id>NI17026J</org_study_id>
    <nct_id>NCT04580108</nct_id>
  </id_info>
  <brief_title>Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus</brief_title>
  <acronym>TROPOPLUS</acronym>
  <official_title>Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Diagnostics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Identification of biological markers able to better stratify cardiovascular risks in systemic&#xD;
      lupus erythematosus patients is needed. We aimed to determine whether serum cardiac troponin&#xD;
      T levels measured with a highly sensitive assay (HS-cTnT) may predict cardiovascular events&#xD;
      in systemic lupus erythematosus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac Troponin (cTnT) is a marker of myocyte necrosis and injury in the early phase of&#xD;
      acute myocardial infarction. Measured with high-sensitivity (HS) assays, HS-cTnT has proven&#xD;
      predictive value for coronary heart disease, heart failure, and mortality in the general&#xD;
      population at apparent low-risk for cardiovascular events. In a previous study, our group&#xD;
      showed that HS-cTnT concentration was associated with subclinical atherosclerosis in systemic&#xD;
      lupus erythematosus patients. The aim of this study was to determine whether HS-cTnT was&#xD;
      associated with incident cardiovascular events in systemic lupus erythematosus&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2007</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">January 17, 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome was the occurrence of cardiovascular events over follow-up.</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Incidents cardiovascular events (CVE) were ascertained by physician interview using a standardized questionnaire and through examination of medical records. cardiovascular events included coronary heart disease, stroke, revascularization procedure for other atherosclerotic cardiovascular diseases and sudden cardiac death. Coronary heart disease was defined as a history of angina, coronary revascularization, or myocardial infarction. All CVE that occurred through March 2019 were considered for analysis</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">446</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Patients with systemic lupus erythematosus</arm_group_label>
    <description>Patients with systemic lupus erythematosus enrolled in the PLUS cohort between 2007 and 2010</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with systemic lupus erythematosus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with a systemic lupus erythematosus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate follow-up period (&lt; 20 months) -past history of CVE at baseline for&#xD;
             inclusion in the TROPOPLUS study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Sacré, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GH Bichat-Claude Bernard, Paris, France, 75018</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Troponin T</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

